A detailed history of Vanguard Group Inc transactions in Mannkind Corp stock. As of the latest transaction made, Vanguard Group Inc holds 15,140,709 shares of MNKD stock, worth $79 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,140,709
Previous 15,248,608 0.71%
Holding current value
$79 Million
Previous $55.5 Million 23.57%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$3.25 - $5.27 $350,671 - $568,627
-107,899 Reduced 0.71%
15,140,709 $68.6 Million
Q4 2023

Feb 14, 2024

BUY
$3.34 - $4.29 $2 Million - $2.57 Million
598,895 Added 4.09%
15,248,608 $55.5 Million
Q3 2023

Nov 14, 2023

BUY
$3.91 - $5.45 $39,713 - $55,355
10,157 Added 0.07%
14,649,713 $60.5 Million
Q2 2023

Aug 14, 2023

BUY
$3.72 - $4.79 $2.41 Million - $3.11 Million
648,548 Added 4.64%
14,639,556 $59.6 Million
Q1 2023

May 15, 2023

BUY
$3.95 - $5.63 $1.29 Million - $1.84 Million
326,780 Added 2.39%
13,991,008 $57.4 Million
Q4 2022

Feb 10, 2023

BUY
$3.02 - $5.37 $1.67 Million - $2.97 Million
553,919 Added 4.23%
13,664,228 $72 Million
Q3 2022

Nov 14, 2022

BUY
$2.99 - $4.35 $824,961 - $1.2 Million
275,907 Added 2.15%
13,110,309 $40.5 Million
Q2 2022

Aug 12, 2022

BUY
$2.67 - $4.77 $139,379 - $249,003
52,202 Added 0.41%
12,834,402 $48.9 Million
Q1 2022

May 13, 2022

BUY
$2.62 - $4.45 $357,960 - $607,985
136,626 Added 1.08%
12,782,200 $47 Million
Q4 2021

Feb 14, 2022

BUY
$4.05 - $5.37 $2.69 Million - $3.56 Million
663,829 Added 5.54%
12,645,574 $55.3 Million
Q3 2021

Nov 12, 2021

SELL
$3.89 - $5.48 $3.56 Million - $5.01 Million
-913,908 Reduced 7.09%
11,981,745 $52.1 Million
Q2 2021

Aug 13, 2021

BUY
$3.61 - $5.45 $46.6 Million - $70.3 Million
12,895,653 New
12,895,653 $70.3 Million

Others Institutions Holding MNKD

About MANNKIND CORP


  • Ticker MNKD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 257,338,000
  • Market Cap $1.34B
  • Description
  • MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...
More about MNKD
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.